Analyzing Infinity Pharmaceuticals (INFI) & The Competition

Infinity Pharmaceuticals (NASDAQ: INFI) is one of 196 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Infinity Pharmaceuticals to similar businesses based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Institutional & Insider Ownership

67.5% of Infinity Pharmaceuticals shares are held by institutional investors. Comparatively, 48.5% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 6.8% of Infinity Pharmaceuticals shares are held by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Infinity Pharmaceuticals and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Infinity Pharmaceuticals 0 1 0 0 2.00
Infinity Pharmaceuticals Competitors 465 2217 6112 117 2.66

As a group, “Biotechnology & Medical Research” companies have a potential upside of 0.41%. Given Infinity Pharmaceuticals’ peers stronger consensus rating and higher possible upside, analysts plainly believe Infinity Pharmaceuticals has less favorable growth aspects than its peers.

Risk and Volatility

Infinity Pharmaceuticals has a beta of 2.63, suggesting that its stock price is 163% more volatile than the S&P 500. Comparatively, Infinity Pharmaceuticals’ peers have a beta of 1.63, suggesting that their average stock price is 63% more volatile than the S&P 500.

Earnings and Valuation

This table compares Infinity Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Infinity Pharmaceuticals N/A -$55.73 million -1.05
Infinity Pharmaceuticals Competitors $207.80 million -$2.20 million 0.14

Infinity Pharmaceuticals’ peers have higher revenue and earnings than Infinity Pharmaceuticals. Infinity Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Infinity Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Infinity Pharmaceuticals N/A -88.08% -59.20%
Infinity Pharmaceuticals Competitors -3,989.00% -119.24% -44.05%

Summary

Infinity Pharmaceuticals peers beat Infinity Pharmaceuticals on 8 of the 12 factors compared.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply